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SUMMARY
Saliva testing is a non-invasive and inexpensive test that can serve as a source of information useful for diagnosis of disease. As we enter 
the era of genomic technologies and –omic research, collection of saliva has increased. Recent proteomic platforms have analysed the hu-
man salivary proteome and characterised about 3000 differentially expressed proteins and peptides: in saliva, more than 90% of proteins 
in weight are derived from the secretion of three couples of “major” glands; all the other components are derived from minor glands, 
gingival crevicular fluid, mucosal exudates and oral microflora. The most common aim of proteomic analysis is to discriminate between 
physiological and pathological conditions. A proteomic protocol to analyze the whole saliva proteome is not currently available. It is pos-
sible distinguish two type of proteomic platforms: top-down proteomics investigates intact naturally-occurring structure of a protein under 
examination; bottom-up proteomics analyses peptide fragments after pre-digestion (typically with trypsin). Because of this heterogeneity, 
many different biomarkers may be proposed for the same pathology. The salivary proteome has been characterised in several diseases: oral 
squamous cell carcinoma and oral leukoplakia, chronic graft-versus-host disease Sjögren’s syndrome and other autoimmune disorders such 
as SAPHO, schizophrenia and bipolar disorder, and genetic diseases like Down’s Syndrome and Wilson disease. The results of research 
reported herein suggest that in the near future human saliva will be a relevant diagnostic fluid for clinical diagnosis and prognosis.
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RIASSUNTO
Lo studio della proteomica salivare, test economico e non invasivo, rappresenta una fonte di numerose informazioni, ed è utile per la diagnosi di sva-
riate malattie. Da quando siamo entrati nell’era della tecnologia genomica e delle scienze “omiche”, la raccolta di campioni salivari è aumentata 
esponenzialmente. Recenti piattaforme proteomiche hanno analizzato il proteoma salivare umano, caratterizzando circa 3000 peptidi e proteine, 
espressi in maniera differente: più del 90% in peso deriva dalla secrezione delle tre ghiandole salivari maggiori, mentre la restante parte proviene 
dalle ghiandole salivari minori, dal fluido crevicolare gengivale, da essudati mucosi e dalla microflora orale. L’obiettivo principale dell’analisi 
proteomica è discriminare tra condizioni fisiologiche e patologiche. Ad oggi, tuttavia, non esiste un preciso protocollo che permetta di analizzare 
l’intero proteoma salivare, pertanto sono state realizzate svariate strategie. Innanzitutto, è possibile distinguere due tipologie di piattaforme prote-
omiche: l’approccio “top-down” prevede l’analisi delle proteine sotto esame come entità intatte; nell’approccio “bottom-up” la caratterizzazione 
della proteina avviene mediante lo studio dei peptidi ottenuti dopo digestione enzimatica (con tripsina tipicamente). A causa di questa eterogeneità, 
per una stessa patologia sono stati proposti differenti biomarkers. Il proteoma salivare è stato caratterizzato in numerose malattie: carcinoma 
squamoso e leucoplachie orali, malattia del trapianto contro l’ospite (GVHD) cronica, sindrome di Sjögren e altri disordini autoimmuni come la 
sindrome SAPHO (sinovite, acne, pustolosi, iperostosi e osteite), schizofrenia e disordine bipolare, malattie genetiche come la sindrome di Down o 
la malattia di Wilson. In conclusione, i risultati delle ricerche riportate in questa review suggeriscono che nel prossimo futuro la saliva diverrà un 
fluido di indubbia rilevanza diagnostica utile per fini clinici, sia diagnostici, sia prognostici.
PAROLE CHIAVE: Saliva • Proteoma • Biomarkers salivari
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Introduction
Saliva is a very attractive body fluid for diagnosis of dis-
ease for many reasons: i) collection of saliva is usually 
economical, safe, easy and can be performed without the 
help of healthcare workers (it allows for home-based sam-
pling); ii) it is considered an acceptable and non-invasive 
process by patients because it does not provoke any pain 
(and can be easily collected for patients in the paediatric 
age range) 1. Recent proteomic platforms have analysed 
the human salivary proteome, characterising about 3000 
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differentially expressed proteins and peptides, many of 
them of microbiological origin 2. A careful evaluation of 
this huge amount of data so far achievable will allow, in 
the near future, to tailor therapeutic interventions by as-
sessment of thousands of parameters. Today, proteomic 
technologies are extremely complex, expensive and of 
limited accessibility. It is, however, not difficult to foresee 
an explosion in -omics research applications in the next 
years, with production of simple, inexpensive and ergo-
nomic instruments, that can be applied to small salivary 
samples for early diagnosis of different pathologies. The 
aim of this review is to briefly describe the most salient 
aspects of current proteomic researches and other –omic 
sciences carried out on human saliva with particular re-
gard to its potential use as a diagnostic fluid and to un-
derline the most demanding and challenging perspectives.
The human saliva proteome
As with any bodily fluid, whole human saliva has specific 
characteristics, and some recent reviews have described 
the distinctiveness of its proteome 3 4. More than 90% in 
weight of the about 3,000 protein components detected in 
saliva 5 are derived from the secretion of three couples of 
“major” glands, parotid, sub-mandibular and sub-lingual 
(Sm-Sl) glands, and pertain to the classes of proline-rich 
proteins (PRPs; divided in acidic, basic and basic glyco-
sylated), α-amylases, mucins, salivary (“S-type”) cysta-
tins, histatins, statherin and P-B peptide. All these com-
ponents and derivatives account for about 200 proteins/
peptides. All the other components detected in saliva rep-
resent the remaining 10% in weight. Some of these, i.e. 
lipocalin, are secreted by minor glands (labial, palatine, 
buccal and lingual, i.e. von Ebner glands) 5, Others, such 
as α-defensins and b-thymosins, derive mainly from gin-
gival crevicular fluid 6 7. Human serum albumin and other 
plasmatic proteins are probably the products of mucosal 
exudates, while others are of exogenous (oral microflora) 
origin.
Major families of secreted salivary proteins are polymor-
phic, and various post-translational modifications (PTMs) 
occur before secretion, such as glycosylation, phospho-
rylation, exo- and endo-proteolytic cleavages, as reported 
in recent reviews 1 3 8. A small percentage of histatin 1 is 
submitted to tyrosine sulphation 9. Cystatin B is detect-
able mainly as S-glutathionyl and S-cysteinyl deriva-
tives 10. The most common aim of proteomic analysis is 
to discriminate between physiological and pathological 
conditions. In the presence of multiple sources, such as 
in the case of salivary glands, quantitative alteration of 
one source might be compensated by others. The compo-
sition of whole saliva varies depending on different physi-
ological conditions. Minor glands secrete during the night 
spontaneously at a low rate. In daytime and at rest, move-
ments of the tongue and lips, and mucosal dryness stimu-
late secretion, particularly by the submandibular gland 
(unstimulated secretion). In response to strong stimuli, 
parotid contributions become more dominant, with a 
flow-rate about twice as high as that from the submandib-
ular gland when chewing. On the whole, the flow rate of 
resting as well as stimulated saliva is higher in the after-
noon than in the morning, the peak occurring in the mid-
dle of the afternoon. Age is another important variable af-
fecting the salivary proteome. Indeed, recent studies have 
indicated that secretion of specific peptides is noticeably 
different in the paediatric age with respect to adults 11 12. 
This dynamism is challenging for proteomic investiga-
tions of human saliva 3 and all sources of variability must 
be carefully considered for choice of the proper control 
group. Nonetheless, because many PTMs occurring dur-
ing glandular secretion are under the action of enzymes 
common to other exocrine and endocrine glands, qualita-
tive and quantitative alterations may be a clue of parallel 
malfunctions of other exocrine and endocrine glands, and 
therefore a signal of systemic diseases.
Proteomic platforms for the study  
of human saliva
Because a proteomic strategy able to characterise the 
whole saliva proteome does not exist 12 and many studies 
on the same disease have been carried out with different 
instruments and experimental plans, it is not surprising 
that different biomarkers have been proposed for the same 
pathology. However, different biomarkers are sometimes 
reported when applying similar platforms to the same pa-
thology, generating legitimate doubts on the robustness 
of the experimental plan utilised, on the number of sam-
ples under study and on the choice of proper controls 13. 
These aspects were nicely outlined in several studies14 15 
showing that the increased number of components under 
observation strongly enhances the possibility to detect 
variations connected to inter-individual polymorphisms. 
With the exception of Sjögren’s syndrome, several studies 
carried out to detect biomarkers in the same disease have 
often produced inconsistent results. It is advised that an 
adequate number of samples are analysed that can provide 
highly significant statistical differences, to strictly follow 
identical experimental protocols for different groups of 
samples and to analyze them in random order. The use of 
ELISA methods for validation of proteomic results has 
also been debated 12, because the antibody utilised may 
not have the proper selectivity to discriminate between 
the proteoforms connecterelated with development of the 
disease.
Different classifications are available for proteomic plat-
forms. Depending on the sample, they are first divided 
into bottom-up and top-down platforms. Top-down pro-
teomics investigates the intact naturally occurring struc-
ture of a protein under examination, avoiding as much as 
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possible any sample alterations. Bottom-up proteomics is 
centered on pre-digestion of the sample (typically with 
trypsin) followed by the analysis of peptide fragments by 
high-throughput analytical methods. The presence of a 
protein in the sample is inferred by the detection of one or 
more of its specific (proteotypic) fragments, implying bi-
univocal correspondence between the parent protein and 
its fragments 12. The majority of proteins are submitted to 
extensive post-translational modifications, cleavages in-
cluded, before reaching a mature functional structure. As 
a consequence, the minimalistic approach of the bottom-
up strategy can result in the relevant loss of important 
molecular information. PTMs are difficult highlight in 
bottom-up shotgun experiments, where the vast majority 
of peptide sequences are often associated with a specific 
cDNA sequence, thus leveling out at a statistical level 
the presence of a PTM. Moreover, the association of 
molecular maturation events associated with the specific 
onset of a defined PTM will not be directly accessible by 
bottom-up shot-gun experiments. This defect is relevant 
for the proteome of human saliva, where many proteins, 
i.e. basic and acidic PRPs, are not very susceptible to the 
action of proteolytic enzymes and disclose very similar 
sequences. Thereby, many fragments cannot be related 
to a specific parent protein. Nonetheless, bottom-up plat-
forms have shown the best throughput in terms of number 
of detected components. The sensitivity of new genera-
tion mass spectrometers is enough to reveal thousands of 
peptides in a single analysis, while the main problem is 
related to the increase in time necessary for the different 
separation steps 16. Therefore, improvements in the sepa-
ration platform utilised in shot-gun proteomics reflect in 
easier peptide detection. In this way, shot-gun proteom-
ics covers the highest range of detectable components, 
regardless of their mass, because the proteolytic diges-
tion of large proteins can almost always generate pro-
teotypic peptides that can disclose the presence of the 
parent protein in a complex mixture. For these reasons, 
the number of salivary components currently detectable 
by shot-gun approaches is more than five times greater 
than the number of components detected by any other 
platform. Top-down platforms are intrinsically limited 
by the sample treatments necessary for coupling with 
mass spectrometry (typically treatment with formic 
acid or trifluoroacetic acid), which inevitably excludes 
proteins that are insoluble in acidic solution. Moreover, 
intact high-molecular weight proteins and heterogene-
ous glycosylated proteins are not accessible, in their 
naturally occurring forms, even to the best high-level 
MS apparatus. Platforms based on 2-D-electrophoresis 
are affected by poor reproducibility and to avoid bias 
it is often necessary to run multiple replica of the same 
sample. The results obtainable by MALDI-TOF-MS are 
strongly dependent on the formation of the matrix layer. 
Therefore, any proteomic platform has advantages and 
drawbacks. For all the above reported reasons, the best 
way to carry out a robust biomarker identification is to 
analyse an adequate number of samples with different 
proteomic methodologies, even though this possibility is 
not accessible to the majority of laboratories 12 15.
Human saliva as diagnostic body fluid
Several excellent reviews have recently been published 
outlining the possibility to use saliva as a diagnostic flu-
id 17-19. As a consequence, we will report only some of the 
most recent research carried out in the last three years, 
apologising for relevant omissions. More than 90% of oral 
cancers are oral squamous cell carcinoma (OSCC). Many 
patients are diagnosed with the tumour at a late state with 
poor prognosis and low survival rate; early diagnosis of 
OSCC is thus urgent problem for clinicians. Many recent 
proteomic studies have been devoted to the search for ear-
ly salivary biomarkers of OSCC and other oral cancers. 
The results obtained add further information to numerous 
previous studies on this topic, which have suggested 17 
up-regulated protein biomarkers 17. Among these, inter-
leukins 6, 8 and 1b, cyclin D1 thioredoxin and profiling 
1 seem to be the most promising. The proteome of sa-
liva from three groups of patients (healthy controls, indi-
viduals with potentially malignant disorders (OPMD) and 
OSCC patients) was investigated by SDS-PAGE coupled 
to LC-MS/MS. In the control, OPMD and OSCC groups 
958, 845 and 1030 salivary proteins were detected, re-
spectively. By label free quantification, 22 overexpressed 
proteins were detected in the OSCC group. Among these, 
resistin (RETN) was validated by ELISA thus confirming 
proteomic data. RETN levels had significant correlation 
with late-stage primary tumours, advanced overall stage 
and lymphnode metastasis 20. The same group used a 
spectral counting-based label free quantification platform 
to identify 64 protein candidates for OSCC 21. Retrieving 
mRNA expression from public-domain based transcrip-
tome data sets, they were able to reduce the number of 
potential candidates to 19. Among these, thrombospon-
din-2 was identified as the best biomarker because higher 
levels were associated with a higher overall pathological 
state, positive perineural invasion and poorer prognosis 21. 
Using nano-LC-MS/MS and validation by Western blot 
and ELISA, Jou et al. 22 were able to identify S100A8 as 
a potential biomarker of OSCC. High level of S100A8 
appeared in 3.4, 13.9, 92.9 and 100% of saliva of OS-
CC patients with T1, T2, T3 and T4 stages, respectively. 
The AUROC curve indicated high sensitivity, specificity 
and accuracy of S100based ELISA as a detector. A com-
parative 2-D electrophoretic analysis of whole saliva of 
patients with OSCC (n = 12) and healthy controls (n = 
12) was able to identify α1-antitrypsin (AAT), hapto-
globin b chains (HAP), complement C3, haemopexin and 
transthyretin as potential OSCC biomarkers, which were 
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validated by ELISA. In particular, a strong association 
of ATT and HAP with OSCC was further supported by 
immunochemical staining of cancer tissues 23. A targeted 
proteomic strategy applying a MS selected reaction moni-
toring (SRM) assay to 14 OSCC candidate biomarker 
proteins suggested that AAT, complement C3, 4B, factor 
B, and leucine-rich α-2-glycoprotein are associated with 
increased risk to develop OSCC 24.
Using an affinity-based depletion method to eliminate 
amylase and albumin coupled to high-resolution MS, Si-
vadasan et al. 25 were able to identify 1256 salivary pro-
teins and to update the salivary proteome to 3449 proteins, 
806 of which were differentially expressed in oral cancer 
tissues 25. The authors provide a list of 139 proteins along 
with their proteotypic peptides, which might serve as a 
reference for targeted investigations as secretory mark-
ers for clinical applications in oral malignancies. A study 
carried out with a 2D-PAGE platform and Western blot 
validation identified (among 880 spots, corresponding to 
151 different gene products) galectine-7 as a good sali-
vary biomarker for OSCC, with a specificity of 90% and 
a sensitivity of 80.5% (n = 10) 26. The search for early 
biomarkers of OSCC was also carried out with transcrip-
tomic and metabolomic platforms and some articles have 
reviewed these topics 18 27. A metabolomic study carried 
out with uHPLC coupled to Q-TOF MS on whole saliva 
from 37 OSCC patients, 32 patients with oral leukopla-
kia (OLK) and 34 healthy subjects showed characteristic 
metabolic signatures for the three groups. A panel of five 
metabolites (phenylalanione, valine, n-eicosanoid acid, 
lactic acid and γ-aminobutyric acid) was selected by sta-
tistical methods. After evaluation of the predictive power 
of the five metabolites, the authors established that valine, 
lactic acid and phenylalanine in combination yielded sat-
isfactory accuracy (0.89 and 0.97), sensitivity (86.5% and 
94.6%), specificity (82.4% and 84.4%) and positive pre-
dictive value (81.6% and 87.5%) in distinguishing OSCC 
from controls and OLK, respectively 28. A similar metabo-
lomic study carried out with hydrophilic interaction chro-
matography (HILIC) coupled to TOF-MS on whole saliva 
of OSCC patients identified five potential biomarkers: 
propionylcholine, N-acetyl-L-phenylalanine, sphinga-
nine, phytosphingosine and S-carboxymethyl-L-cysteine. 
Their combination yielded satisfactory accuracy (0.977), 
sensitivity (100%) and specificity (96.7%) in distinguish-
ing early stage of OSCC from controls 29.
Recent research has suggested that potential biomarkers 
in other cancer types may be present in human saliva. A 
study carried out by nano-HPLC-Q-TOF MS investigated 
the proteome profiles of plasma and saliva of patients 
with fibroadenoma (n = 10), infiltrating ductal carcinoma 
(n = 10) and healthy controls (n = 8). The major differ-
entially expressed proteins in the saliva of patients com-
pared with controls were α2-macroglobulin and cerulo-
plasmin, which should be further validated as potential 
biomarkers of impalpable breast lesions 30. A differential 
proteomic analysis using tandem mass tags technology 
was performed to characterise potential salivary biomark-
ers for gastric cancer detection. More than 500 proteins 
were identified and quantified, and three were successful-
ly verified by ELISA, namely cystatin B, triose-phosphate 
isomerase and a protein called “deleted in malignant tu-
mor 1 protein”. The combination of these three biomark-
ers could reach 85% sensitivity and 80% specificity for 
the detection of gastric cancer with accuracy of 0.93 31. 
A 2D-electrophoretic analysis coupled off-line with MS 
identification of the tryptic digest of the spots identified 
22 proteins selectively expressed in patients with oral leu-
koplakia 32. Immunohistochemical validation suggested 
that keratin 10 was an interesting potential biomarker 
of OLK and should be further investigated. A transcrip-
tomic platform identified five mRNA biomarkers (CCNI, 
EGFR, FGF19, FRS2 and GREB1) that after logistic re-
gression model can differentiate lung cancer patients from 
normal subjects 33.
The proteome of saliva seems to have the potential to dis-
criminate many other diseases. Two groups have investi-
gated whole human saliva to find potential signatures in 
oral chronic graft-versus-host-disease (cGVHD), a severe 
immunological complication occurring after allogeneic 
haematopoietic stem cell transplantation 34 35. A LC-MS/
MS study observed a reduction of salivary lactoperoxi-
dase, lactotransferrin and several proteins included in the 
cysteine proteinase inhibitor family suggesting impaired 
oral antimicrobial host immunity in cGVHD patients 34. 
Another study performed utilising iTRAQ labeling fol-
lowed by HPLC-ESI-MS/MS and ELISA validation 
showed decreased expression of IL-1 receptor antagonist 
and cystatin B in saliva of patients with active oral cG-
VHD. ROC analysis revealed that these two markers were 
able to distinguish oral cGVHD with a sensitivity of 85% 
and specificity of 60% 35.
Many proteomic studies in the past were devoted to the 
characterisation of salivary biomarkers of Sjögren’s syn-
drome (pSS) and this topic has been reviewed in depth 36-38. 
A recent study investigated the expression of thymosins 
b4 and b10 in patients with pSS and in patients with au-
toimmune diseases: systemic sclerosis [SSc], systemic lu-
pus erythematosus [SLE] and rheumatoid arthritis [RA], 
with and without sicca syndrome [ss]. This research 
showed that higher salivary Tb expression characterised 
patients with pSS, while Tb
4
 sulfoxide and Tb
10
 salivary 
expression were selectively present in patients with sicca 





in patients with pSS who have ss and other autoimmune 
disease 39. A metabolomic analysis of saliva from patients 
with pSS carried out with a GC-MS platform was able 
to detect a total of 88 metabolites, 41 of which were ob-
served at reduced levels in samples from pSS patients. 
The reduced presence of glycine, tyrosine, uric acid and 
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fucose observed might reflect salivary gland destruction 
due to chronic sialoadenitis 40. A top-down HPLC-ESI-
MS and MS/MS platform was able to detect a signature 
in whole saliva of patients with synovitis, acne, pustulo-
sis, hyperostosis and osteitis (SAPHO) syndrome, another 
rare, often unrecognised, rheumatological disease with 
prominent inflammatory cutaneous and articular symp-
toms characterised by musculoskeletal manifestations 
(synovitis, hyperostosis, osteomyelitis) associated with 
dermatological conditions (severe acne and pustulosis). 
The acidic soluble fraction of whole saliva from 10 adult 
women affected by SAPHO syndrome and from a group 
of 28 healthy women was analysed by RP-HPLC-ESI-
MS and showed a significantly decreased concentration 
of cystatin S1 and SN, histatins, the major acidic PRPs, 
P-C and P-B peptides in saliva of SAPHO subjects with 
respect to controls. Histatins showed positive correlations 
with C reactive protein, cystatin S1, histatins 3, histatin 5 
and a positive correlation with the neutrophil count, while 
histatin 3 correlated positively with total white cell count 
and negatively with the erythrocyte sedimentation rate. 
The levels and frequency of S100A12 protein showed a 
trend to increase in SAPHO patients, which was probably 
related to the inflammatory response and to the altered 
neutrophil responses to functional stimuli that character-
ize SAPHO syndrome, suggesting a possible application 
as a salivary biomarker 41.
Proteomics of saliva can contribute to the detection of 
early markers of psychiatric diseases 42. A recent study 
carried out with a top-down HPLC-ESI-MS and MS/MS 
platform investigated whole saliva of 32 subjects with di-
agnosis of schizophrenia (SZ), 17 with diagnosis of bi-
polar disorder (BD) and 31 healthy subjects divided in 
non-smokers (HN; n = 19) and smokers (HS; n = 12) Both 
SZ and BD revealed more than 10 fold mean increase of 
α-defensins 1-4, S100A12, cystatin A and S-derivatives 
of cystatin B levels with respect to the HN and HS control 
groups. This study confirmed schizophrenia-associated 
dysregulation of a immune pathway of peripheral white 
blood cells and suggested that the dysregulation in the 
BD group could involve the activation of more specific 
cell type than that of SZ group 43. A proteomic analysis of 
saliva in HIV-positive heroin addicts performed by a lon-
gitudinal HPLC-MS based quantitative platform investi-
gated saliva samples taken from 8 HIV-positive (HIV+) 
and 11 -negative (HIV-) heroin addicts. In addition, saliva 
samples were investigated from 11 HIV- non-heroin ad-
dicted healthy controls. In the HIV+ group, 58 proteins 
were identified that show significant correlations with 
cognitive scores, implicating disruption of protein quality 
control pathways by HIV 44.
Saliva proteome was able to detect signatures that are 
characteristics of genetic diseases. Whole saliva of 36 
Down’s syndrome subjects, divided in age groups 10-
17 yr and 18-50 yr, was analysed by a top-down prot-
eomic approach, and the HPLC-ESI-MS profiles were 
compared with sex- and age-matched control groups. 
The main results suggested that levels of the antimicro-
bial α-defensins 1 and 2 and histatins 3 and 5 were sig-
nificantly increased in whole saliva of older Down’s syn-
drome subjects with respect to controls and that S100A7, 
S100A8, and S100A12 levels were significantly increased 
in whole saliva of Down’s syndrome subjects in compari-
son with controls. The increased levels of S100A7 and 
S100A12 may be of particular interest as a biomarker of 
early onset of Alzheimer’s disease, which is frequently 
associated with Down’s syndrome 45. A proteomic analy-
sis was carried out by a top-down proteomic platform on 
whole saliva of Wilson’s disease patients. Wilson’s dis-
ease is a rare inherited disorder of copper metabolism, 
manifesting hepatic, neurological and psychiatric symp-
toms. The qualitative/quantitative characterisation of the 
salivary proteome/peptidome of 32 Wilson’s disease pa-
tients exhibited significant higher levels of S100A9 and 
S100A8 proteoforms, and their oxidised forms with re-
spect to controls. Oxidation occurred on methionine and 
tryptophan residues, and on the unique cysteine residue, 
in position 42 in S100A8, and 3 in S100A9, that generated 
glutathionylated, cysteinylated, sulphinic, sulphonic, and 
disulphide dimeric forms. These findings showed that the 
salivary proteome of Wilson’s disease patients reflected 
oxidative stress and inflammatory conditions characteris-
tic of the pathology 46.
A quantitative proteomic analysis based on limited protein 
separation within the zone of the stacking gel of the 1D 
SDS-PAGE and using isotope-coded synthetic peptides as 
internal standards was employed to study the whole saliva 
proteome of HIV-1 infected individuals. Expression levels 
of members of the calcium-binding S100 protein family 
and “deleted in malignant brain tumours 1 protein” were 
up-regulated, while that of mucin 5B was down-regulated 
in HIV-1 seropositive saliva samples, suggesting new per-
spectives for monitoring HIV-infection and understand-
ing the mechanism of HIV-1 infectivity 47. Since whole 
saliva contains variegate microflora, several platforms 
were recently developed to investigate the human salivary 
metaproteome. A platform combined protein dynamic 
range compression (DRC), multidimensional peptide frac-
tionation and high-mass accuracy MS/MS with a two-step 
peptide identification method using a database of human 
proteins plus those translated from oral microbe genomes 
was recently studied. Peptides were identified from 124 
microbial species. Streptococcus, Rothia, Actinomyces, 
Prevotella, Neisseria, Veilonella, Lactobacillus, Seleno-
monas, Pseudomonas, Staphylococcus and Campylobac-
ter were abundant among the 65 genera from 12 phyla 
represented. Taxonomic diversity was broadly consistent 
with metagenomic studies of saliva 48. A bottom-up shot-
gun nano-HPLC-ESI-MS platform was applied to saliva 
samples of 10 patients with periodontitis, 10 patients with 
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dental caries and 10 orally healthy individuals detecting 
a total of 35,664 unique peptides from 4,161 different 
proteins, of which 1,946 and 2,090 were of bacterial and 
human origin, respectively. The human protein profiles 
displayed significant overexpression of the complement 
system and inflammatory markers in periodontitis and 
dental caries compared to healthy controls, while bacte-
rial proteome profiles and functional annotation were very 
similar in health and disease. Similar bacterial proteomes 
in healthy and diseased individuals suggests that the sali-
vary microbiota predominantly thrives in a planktonic 
state expressing no disease-associated characteristics of 
metabolic activity 49.
Conclusions
Saliva is already used routinely by clinical laboratories 
for detection of secretory IgA antibodies, determination 
of salivary cortisol, hormones and for genetic purposes. 
However, the results of the research reported in this review 
suggest that in the near future human saliva will be a rel-
evant diagnostic fluid for clinical diagnosis and prognosis. 
The application of holistic technologies such as proteom-
ics and other –omic sciences to saliva should soon provide 
a picture of the incredible complexity of each individual, 
capturing his/her distinct and unique metabolic finger-
print and the pathways involved in the health/disease state 
transition and its reverse. Omic sciences are contribut-
ing to the identification and characterisation of salivary 
components, including DNA, RNA, proteins, metabolites 
and microorganisms. Saliva may contain real-time infor-
mation describing our overall physiological condition. 
The -omic studies are showing that, like blood and tissue 
biopsies, oral fluids can be a source of biochemical data 
capable of detecting diseases, not only restricted to local 
disorders like oral cancer and Sjögren’s syndrome, but 
systemic pathologies like genetic, autoimmune, cardio-
vascular and metabolic diseases as well as viral/bacterial 
infections and cancers. The main advantage is its easy and 
non-invasive collection. Moreover, several recent studies 
are demonstrating that the proteome of whole saliva can 
be divided in several subproteomes, because this body 
fluid derives from the contribution of different sources. 
The future increase of the selectivity, resolution and sen-
sitivity of the proteomic MS-based platforms will allow 
proteomes deriving from these different sources to be in-
vestigated in greater detail. The metaproteomic analyses 
of human oral microbiota 48 49 are a nice example of ex-
ploitation of subproteomes of saliva for future diagnosis 
of infectious and opportunistic diseases. Moreover, hu-
man saliva contains extracellular vesicles 50 that can be 
easily separated and utilised for diagnosis of a large set 
of diseases with particular regard for cancer. Even though 
this topic must still be largely explored, a recent study 
showed the feasibility of the analysis of the subproteome 
offered by oral vesicles established that it can contribute 
to early diagnosis and prognosis of OSCC  51. Another 
interesting oral subproteome is constituted by gingival 
crevicular fluid, arising from the gingival plexus of blood 
vessels in the gingival corium, subjacent to the epithelium 
lining the dento-gingival space, as it contains a diverse 
population of cells, including bacteria from the adjacent 
plaque mass, transmigrating leucocytes and desquamated 
epithelial cells, which are passively washed out into the 
oral cavity 52. Its proteome and peptidome has been al-
ready investigated 52-54. This fluid could be useful for the 
discovery of novel periodontal disease markers 55. 
Nonetheless, the efforts needed to reach the above aims 
are still demanding. An emblematic example is represent-
ed by various proteomic studies performed to find salivary 
biomarkers of OSCC. It is surprising that many of these 
studies showed little overlap. The only potential biomark-
ers common to several proteomic studies on OSCC were 
ATT and some components of the complement, which 
should be largely investigated to establish their sensitivity, 
specificity, accuracy and positive predictive value. As dis-
cussed in the previous sections, since different proteomic 
platforms cover different proteomes, it is not surprising 
that different proteomic methodologies identify different 
biomarkers. However, if the proteomic platforms utilised 
are similar, the disagreement could partly derive from the 
low number of patients available in different clinical cent-
ers (fortunately). Due to the medical relevance of OSCC, 
it seems opportune to organise a network of proteomic 
laboratories to share samples and results of similar pa-
thologies and to organise multicentre research to identify 
biomarkers characterised by highly significant statistical 
parameters that can be soon transferred to routine clinical 
use.
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